Association Between Uric Acid / High Density Lipoprotein Ratio and Monocyte / High Density Lipoprotein Ratio with Diabetic Complications

December 24, 2024 updated by: Mennat Allah Gamal Abdelnaser, Assiut University
Type 2 diabetes mellitus (T2DM) poses a formidable global health challenge, with complications arising in both the microvascular and macrovascular domains as glycemic control worsens.the aim of the study to evaluate uric acid / high density lipoprotein cholesterol ratio and monocyte / high density lipoprotein ratio in studied groups. Association between Uric Acid / high density lipoprotein cholesterol ratio and monocyte / high density lipoprotein cholesterol ratio and diabetic Complications (macrovascular and microvascular).

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Hemoglobin A1c (HbA1c) continues to serve as the primary retrospective marker to assess glycemic management, but the inability to monitor daily blood glucose fluctuations remains a persistent concern

Uric acid is the final enzymatic product of purine nucleoside and free base degradation. Elevated levels of serum uric acid (SUA) are widely recognized as a risk factor for macrovascular and microvascular complications. Hyperuricemia is particularly common in patients with hyperlipidemia.

It has been established that SUA levels are proportional to triglyceride (TG), total cholesterol (TC), and low-density lipoprotein (LDL) levels. SUA promotes the oxidation of LDL, which is considered to be a key event in atherosclerotic plaque formation. The findings of several epidemiological studies have thus provided evidence to indicate a clear independent association between elevated SUA levels and an increased incidence of atherosclerotic disease or mortality Decreased serum levels of High-density lipoprotein cholesterol (HDL-c) are proposed to be related to worse metabolic status and reduced HDL-c is even a marker of metabolic syndrome.

A combination of these two metabolic parameters uric acid to HDL-c ratio (UHR) which is a more useful predictor of metabolic deterioration High-density lipoprotein- cholesterol acts by reducing proinflammatory responses triggered by monocytes, effectively restricting monocyte proliferation, activation and migration, and plays a role in the anti-oxidant mechanism. In contrast, reduced levels of HDL-c in the blood stream imply a worsening metabolic profile and are a component of the metabolic syndrome Uric acid can cause atherosclerosis and insulin resistance by reducing nitric oxide production, promoting vascular smooth muscle proliferation, and resulting in endothelial dysfunction. Additionally, low levels of HDL-c play a role in the development of metabolic syndrome and insulin resistance.

More recently, the uric acid-to-HDL-c ratio (UHR) has been identified as a marker that increases in inflammatory conditions . Monocytes and macrophages play crucial roles in damage to pancreatic islet cells, islet inflammation and impaired insulin signaling in T2DM. The monocyte/ HDL-c ratio (MHR) has been proposed as an indicator of ongoing low-grade metabolic inflammation and has been suggested studies to be used as a marker for cardiovascular disease and chronic kidney disease .

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mennat Allah Gamal Abdelnaser, resident doctor
  • Phone Number: +201157429995
  • Email: menaagamal23@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

diabetic patients who attending the Diabetes Clinic of Internal Medicine Department, Assiut University Hospital from January 2025 till January 2026.

Description

Inclusion Criteria:

  • type 2 diabetic patients
  • age more than 18 years old
  • both sex

Exclusion Criteria:

  • Individuals with malignancies, pregnant women, those using furosemide, thiazide, acetylsalicylic acid, losartan group drugs, cholesterol lowering drugs, patients with other autoimmune disorders, patients with chronic kidney disease and gout.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
group 1
Diabetic patients without any macrovascular and microvascular Complications.
group 2
Diabetic patients with macrovascular (stroke, coronary heart disease, Peripheral artery disease) and microvascular (DN and DR) complications
group 3
Apparent healthy subjects as control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
uric acid / high density lipoprotein cholesterol ratio
Time Frame: baseline
Calculation of UHR was calculated by dividing serum uric acid value by HDL-c value
baseline
monocyte / high density lipoprotein ratio
Time Frame: baseline
calculated by dividing of count of monocyte by HDL-c level
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2025

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

December 24, 2024

First Submitted That Met QC Criteria

December 24, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 24, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HDL Uric UHR monocyte MHR DM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe